Published : May-2019
No. of Pages : 45
1.1 List of Tables
1.2 List of Figures
2 Obesity: Executive Summary
2.1 The Need for Further Novel Therapies
2.2 Pipeline Shows Increasing Innovation
2.3 Deals Landscape presents Investment Opportunities
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Obesity
4.4 Epidemiology for Obesity
4.5 Overview for Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between Obesity Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Products to First-in-Class Molecular Target within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting BMPR2
6.3 Pipeline Programs Targeting BMPR1A
6.4 Pipeline Programs Targeting FADS1
6.5 Pipeline Programs Targeting BMPR1B
6.6 Pipeline Programs Targeting SLC27A2
6.7 Pipeline Programs Targeting SREBF1
6.8 Pipeline Programs Targeting ADIPOQ
6.9 Pipeline Programs Targeting C3AR1
6.10 Pipeline Programs Targeting ACACB
7 Key Players and Deals
7.1 Overview
7.1.1 Zafgen Licensing Deal with Children's Medical Center Corporation
7.1.2 Diasome Pharmaceuticals Signs Licensing Deal with SDG
7.1.3 Evotec Co-development Deal with Eternygen
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.3.1 Market Analysis
8.3.2 Overall Pipeline Analysis
8.3.3 First-in-Class Pipeline Analysis
8.3.4 First-in-Class Matrix Assessment
8.3.5 First-in-Class Molecular Target Evaluation
8.3.6 Key Players and Deals
8.4 About the Authors
8.4.1 Analyst
8.4.2 Therapy Area Director
8.4.3 Global Director of Therapy Analysis and Epidemiology
8.4.4 Global Head and EVP of Healthcare Operations and Strategy
8.5 About GlobalData
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Nutritional status
Table 2: Obesity Total Prevalent Cases (Millions), 2012-2022
1.2 List of Figures
Figure 1: Obesity, Global Market by Molecular Target and Molecule Type, 2019
Figure 2: Obesity, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 3: Obesity Global Pipeline, by Molecular Target and Stage of Development, 2019
Figure 4: Obesity, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 5: Obesity, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 6: Obesity, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 7: Obesity, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
